6 Aptamers for Targeted Therapy
167
syndromes undergoing percutaneous coronary intervention: results from the phase II RADARPCI study. Eurointervention 10(4):431–438
46. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE,
Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N,
Zelenkofske SL, Becker RC, Alexander JH, Investigators R (2013) A Phase 2, randomized,
partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results
of the RADAR trial. Eur Heart J 34(31):2481–2489
47. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E,
Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker
RC (2010) First clinical application of an actively reversible direct factor IXa inhibitor
as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Circulation 122(6):614–622
48. Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang
Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF,
Levinson AI, Investigators R-P (2016) Pre-existing anti-PEG antibodies are associated with
severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin
Immunol 138(6):1712–1715
49. Gottenberg JE, Chiocchia G (2007) Dendritic cells and interferon-mediated autoimmunity.
Biochimie 89(6–7):856–871
50. Lee PP, Ramanathan M, Hunt CA, Garovoy MR (1996) An oligonucleotide blocks interferongamma signal transduction. Transplantation 62(9):1297–1301
51. Tuleuova N, Jones CN, Yan J, Ramanculov E, Yokobayashi Y, Revzin A (2010) Development
of an aptamer beacon for detection of interferon-gamma. Anal Chem 82(5):1851–1857
52. Cao B, Hu Y, Duan J, Ma J, Xu D, Yang XD (2014) Selection of a novel DNA aptamer for
assay of intracellular interferon-gamma. PLOS ONE 9(5):e98214
53. Pratico ED, Sullenger BA, Nair SK (2013) Identification and characterization of an agonistic
aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther 23(1):35–43
54. Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP,
Hershfield MS (2016) Pre-existing anti-polyethylene glycol antibody linked to first-exposure
allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol
137(5):1610–1613 e1617
55. Kuhlmann M, Hamming JBR, Voldum A, Tsakiridou G, Larsen MT, Schmokel JS, Sohn E,
Bienk K, Schaffert D, Sorensen ES, Wengel J, Dupont DM, Howard KA (2017) An albuminoligonucleotide assembly for potential combinatorial drug delivery and half-life extension
applications. Mol Ther Nucleic Acids 9 (2162–2531 Print):284–293
56. Roloff A, Carlini AS, Callmann CE, Gianneschi NC (2017) Micellar thrombin-binding
aptamers: reversible nanoscale anticoagulants. J Am Chem Soc 139(46):16442–16445
57. Schmokel J, Voldum A, Tsakiridou G, Kuhlmann M, Cameron J, Sorensen ES, Wengel J,
Howard KA (2017) Site-selective conjugation of an anticoagulant aptamer to recombinant
albumins and maintenance of neonatal Fc receptor binding. Nanotechnology 28(20):204004
58. Waters EK, Genga RM, Thomson HA, Kurz JC, Schaub RG, Scheiflinger F, McGinness KE
(2013) Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction
with multiple domains of the protein. J Thromb Haemost 11(6):1137–1145
59. Gissel M, Orfeo T, Foley JH, Butenas S (2012) Effect of BAX499 aptamer on tissue factor
pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res
130(6):948–955
60. Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE (2011) Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting
tissue factor pathway inhibitor. Blood 117(20):5514–5522
61. Chang JY, Chantrathammachart P, Monroe DM, Key NS (2012) Studies on the mechanism of
action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb Res
130(3):e151–e157
167
syndromes undergoing percutaneous coronary intervention: results from the phase II RADARPCI study. Eurointervention 10(4):431–438
46. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE,
Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N,
Zelenkofske SL, Becker RC, Alexander JH, Investigators R (2013) A Phase 2, randomized,
partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results
of the RADAR trial. Eur Heart J 34(31):2481–2489
47. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E,
Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker
RC (2010) First clinical application of an actively reversible direct factor IXa inhibitor
as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Circulation 122(6):614–622
48. Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang
Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF,
Levinson AI, Investigators R-P (2016) Pre-existing anti-PEG antibodies are associated with
severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin
Immunol 138(6):1712–1715
49. Gottenberg JE, Chiocchia G (2007) Dendritic cells and interferon-mediated autoimmunity.
Biochimie 89(6–7):856–871
50. Lee PP, Ramanathan M, Hunt CA, Garovoy MR (1996) An oligonucleotide blocks interferongamma signal transduction. Transplantation 62(9):1297–1301
51. Tuleuova N, Jones CN, Yan J, Ramanculov E, Yokobayashi Y, Revzin A (2010) Development
of an aptamer beacon for detection of interferon-gamma. Anal Chem 82(5):1851–1857
52. Cao B, Hu Y, Duan J, Ma J, Xu D, Yang XD (2014) Selection of a novel DNA aptamer for
assay of intracellular interferon-gamma. PLOS ONE 9(5):e98214
53. Pratico ED, Sullenger BA, Nair SK (2013) Identification and characterization of an agonistic
aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther 23(1):35–43
54. Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP,
Hershfield MS (2016) Pre-existing anti-polyethylene glycol antibody linked to first-exposure
allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol
137(5):1610–1613 e1617
55. Kuhlmann M, Hamming JBR, Voldum A, Tsakiridou G, Larsen MT, Schmokel JS, Sohn E,
Bienk K, Schaffert D, Sorensen ES, Wengel J, Dupont DM, Howard KA (2017) An albuminoligonucleotide assembly for potential combinatorial drug delivery and half-life extension
applications. Mol Ther Nucleic Acids 9 (2162–2531 Print):284–293
56. Roloff A, Carlini AS, Callmann CE, Gianneschi NC (2017) Micellar thrombin-binding
aptamers: reversible nanoscale anticoagulants. J Am Chem Soc 139(46):16442–16445
57. Schmokel J, Voldum A, Tsakiridou G, Kuhlmann M, Cameron J, Sorensen ES, Wengel J,
Howard KA (2017) Site-selective conjugation of an anticoagulant aptamer to recombinant
albumins and maintenance of neonatal Fc receptor binding. Nanotechnology 28(20):204004
58. Waters EK, Genga RM, Thomson HA, Kurz JC, Schaub RG, Scheiflinger F, McGinness KE
(2013) Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction
with multiple domains of the protein. J Thromb Haemost 11(6):1137–1145
59. Gissel M, Orfeo T, Foley JH, Butenas S (2012) Effect of BAX499 aptamer on tissue factor
pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res
130(6):948–955
60. Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE (2011) Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting
tissue factor pathway inhibitor. Blood 117(20):5514–5522
61. Chang JY, Chantrathammachart P, Monroe DM, Key NS (2012) Studies on the mechanism of
action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb Res
130(3):e151–e157